Chemomab Therapeutics (CMMB) Net Income towards Common Stockholders Growth (1y) (2018 - 2025)
Chemomab Therapeutics (CMMB) Net Income towards Common Stockholders Growth (1y) (2018 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Chemomab Therapeutics |
923.51 Mn |
913.15 Mn |
- |
35.34% |
| Date | Value |
|---|
| Dec 31, 2025 |
35.34% |
| Sep 30, 2025 |
-49.99% |
| Dec 31, 2024 |
-829.50% |
| Sep 30, 2024 |
-16.89% |
| Jun 30, 2024 |
-54.05% |
| Mar 31, 2024 |
-55.60% |
| Dec 31, 2023 |
-58.59% |
| Sep 30, 2023 |
-48.13% |
| Jun 30, 2023 |
8.57% |
| Mar 31, 2023 |
270.67% |
| Dec 31, 2022 |
263.86% |
| Sep 30, 2022 |
372.24% |
| Jun 30, 2022 |
362.74% |
| Dec 31, 2019 |
-610.25% |
| Sep 30, 2019 |
572.17% |
| Jun 30, 2019 |
-66.36% |
| Mar 31, 2019 |
426.52% |
| Dec 31, 2018 |
-1.69% |
